Sign in
4

Changes in Ownership

VERTEX PHARMACEUTICALS INC / MA Filed Acc 0001209191-23-024312

EVP, Cell & Genetic Therapies sold 7,567 shares at an average $326.70 ($2,472,164)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Sanna Bastiano · EVP, Cell & Genetic Therapies

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2023-04-12 Sale : show line 1 in the form 10b5-1 −874 $325.70 $284,662 46,406 D
2023-04-12 Sale : show line 2 in the form 10b5-1 −4,068 $326.45 $1,327,999 42,338 D
2023-04-12 Sale : show line 3 in the form 10b5-1 −2,625 $327.43 $859,504 39,713 D
Open-market sales · 7,567 sh · avg $326.70 · $2,472,164
Loading xslF345X04/doc4.xml…